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Abstract
Transcription factors have an important role in cancer but are difficult targets for the devel-
opment of tumour therapies. These factors include the Ets family, and in this study Elk3 that
is activated by Ras oncogene /Erk signalling, and is involved in angiogenesis, malignant
progression and epithelial-mesenchymal type processes. We previously described the
identification and in-vitro characterisation of an inhibitor of Ras / Erk activation of Elk3 that
also affects microtubules, XRP44X. We now report an initial characterisation of the effects
of XRP44X in-vivo on tumour growth and metastasis in three preclinical models mouse
models, subcutaneous xenografts, intra-cardiac injection-bone metastasis and the TRAMP
transgenic mouse model of prostate cancer progression. XRP44X inhibits tumour growth
and metastasis, with limited toxicity. Tumours from XRP44X-treated animals have
decreased expression of genes containing Elk3-like binding motifs in their promoters, Elk3
protein and phosphorylated Elk3, suggesting that perhaps XRP44X acts in part by inhibiting
the activity of Elk3. Further studies are now warranted to develop XRP44X for tumour
therapy.
Introduction
Transcription factors are potent drivers of cell transformation, and targeting their activity can
be highly effective for tumour therapy [1]. Transcription factors of the Ets family play impor-
tant role in tumorigenesis [2] and are being used as targets to develop therapies [3]. We showed
that the Elk3 member of the Ets family is a potential target for tumour therapy. Elk3 can act as
either a repressor of transcription or an activator following phosphorylation by Erk1/2 in
response to growth factor activation of the Ras pathway [4]. Elk3 is downregulated by hypoxia
and regulates hypoxia-responsive genes [5–7]. Elk3 is involved in angiogenesis [8–12],
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malignant progression of squamous cell carcinoma [13], cell adhesion, migration and invasion
[14–16], and differentiation from progenitor to definitive neural crest cell [17]. We identified
an inhibitor of Ras-activated Elk3 transcription-factor activity, XRP44X, in a cell based screen
of a small-molecule library [18]. The scaffold of XRP44X is pyrazole, which is considered to be
very useful for the development of anticancer agents [19]. XRP44X was found to inhibit fibro-
blast growth factor 2 (FGF-2)-induced Elk3 phosphorylation by the Ras-Erk signaling at some
point in the pathway upstream from Ras. It was also found to bind to the colchicine-binding
site of tubulin, to depolymerize microtubules, to stimulate blebbing of the cell membrane and
to alter the actin skeleton.
Various classes of tubulin directed agents have been identified. They are considered to be
clinically significant because they have a broad spectrum of effects that include cell division,
intracellular trafficking, cell signalling, cell migration and angiogenesis [20]. Microtubule-tar-
geting agents can either stabilise or destabilise microtubules [21]. We found that XRP44X and
the destabiliser, Combretastin-A4, have similar effects on the cytoskeleton and FGF-2 Ras-Elk3
signalling, and they differ from other classes of agents, and in particular docetaxel, that stabi-
lises microtubules. [18]. At least some of these effects of XRP44X are mediated by c-Jun N-ter-
minal kinase [22]. These in-vitro properties encouraged the investigation of the therapeutic
properties of XRP44X in pre-clinical cancer models.
Preclinical models are indispensable in the drug discovery and development even though
they are imperfect replicas of human cancers. There are various preclinical tumour models,
including traditional ectopic xenografts and genetically engineered tumour models, that repre-
sent a portfolio of test systems that are used in a hierarchical manner [23]. We have undertaken
an initial evaluation of XRP44X in order to broadly establish its efficacy and toxicity. We used
well established models of increasing complexity, including several ectopic xenografts in nude
mice that generate metastases (subcutaneous xenografts and cardiac injection of tumour cell
lines) and the transgenic adenocarcinoma mouse prostate (TRAMP) model [24] that is amena-
ble to drug testing [25]. We found that XRP44X inhibits tumour growth and metastasis with
limited toxicity by a mechanism that involves Elk3. These results encourage further investiga-
tion of XRP44X for tumour therapy in humans.
Materials and Methods
Cell Lines, Culture Conditions and Growth Curves
The cell lines C6 (ATCC CCL-107) and LL/2 (LLC1) (ATCC CRL-1642) were propagated at
37°C with 5% CO2 in complete medium (see the ATCC webpages for compositions, C6, LL/2).
All cell lines were tested to ensure they were mycoplasma free.
Animals
Animal experiments performed in the IGBMC conformed to French laws, including the latest
Decree 2013–118 of 1 February 2013 on the protection of animals used for scientific purposes
and the Decree of 1 February 2013 on the ethical evaluation and authorization of projects
involving the use of animals in experimental procedures. Ethical issues were overseen by
Com'Eth, the local ethics committee for animal experimentation. Com'Eth is registered with
the Ministry of Research and the National Ethics Committee for Animal Experimentation
Thinking under number 17. Animal well-being is considered in the ethical approvals and is
supervised and enforced by the Animal Well-being Committee of the IGBMC, in close collabo-
ration with Com’Eth. The Well-being Committee was established following the Directive 2010/
63 (decrees and orders of February 1, 2013; Art. R. 214–102; Art. R. 214–103, Art. 4.–I; Art. 9.–
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in application of R. 214–126). Animal experiments performed in LUMC followed the guide-
lines established in the Netherlands for the care and use of laboratory animals (DEC 4077).
Humane endpoints were in place, and animals were euthanized to prevent unnecessary suf-
fering, following the general published guidelines [26] and the recommendations of the Ethical
Committees. Tumour burden was limited to the minimum required for a valid scientific out-
come, and before there were clinical signs that necessitate immediate intervention (see Box 5 in
[26]). Animals were monitored daily for general and clinical signs of potential adverse effects
(eating, drinking, weight change, persistent hypothermia, discharge, respiration, enlarged
lymph nodes or spleen, weakness, paralysis, anaemia, incontinence, diarrhoea, general behav-
iour and pain). There were no euthanized mice in the xenograft experiments. Several TRAMP
mice were euthanized, mainly near the end of the treatment, due the presence of palpable
tumours and persistent weight gain. They corresponded to 5 control and 1 XRP44X treated
TRAMPmice, 40, 57, 69, 83 and 88 versus 85 days after the start of treatment of the 98 day pro-
tocol. These mice were included in the protocol. Two wild-type mice were lost, due to
unknown causes.
Subcutaneous Xenografts in Nude Mice
Male nude mice (BALB/c nu/nu; Charles River, L’Arbresle, France) were housed in ventilated
cages under sterile conditions. C6 and LL/2 (LLC1) cells were detached with trypsin, resus-
pended in PBS and injected subcutaneously in the left flank of 8 week old female BALB/c nu/
nu nude mice (200 μl containing 105 C6 or 106 LL/2 (LLC1) cells, 10 mice per cell line). The
smaller and larger tumour diameters were measured with callipers every day, and tumour vol-
umes were calculated [V = 4/3 x π x (1/2 x smaller diameter)2 x (1/2 x larger diameter)]. After
about 6 days, when the tumour volumes were about 30 mm3, the mice were injected intraperi-
toneally every day with 200 μl of XRP44X (0.1 mM XRP44X in 30% DMSO in PBS) or solvent
alone (control) for about 25 days. The mice were anaesthetised (100 μl 25% Imalgen 1000, 15%
Rompun in 0.9% NaCl), the primary tumours were excised and frozen in dry ice. The mice
were then perfused with fixative (4% paraformaldehyde, 3% glutaraldehyde in PBS), organs
were removed and immersed in fixative. Similar results were obtained in three separate
experiments.
Metastasis-to-Bone Mouse Model
Male nude mice (BALB/c nu/nu; Charles River, L’Arbresle, France) were housed in individual
ventilated cages under sterile conditions Mice were anesthetized before all surgical and analyti-
cal procedures. A single-cell suspension of 1 × 105 PC-3M-Pro4/luc or PC-3MPro4/luc2 cells/
100 μl PBS was injected into the left cardiac ventricle of 4-week-old BALB/c nu/nu nude male
mice. The progression of cancer cell growth was monitored by bioluminescent imaging (BLI)
using the IVIS100 Imaging System (Caliper Life- Sciences, Hopkinton, MA). Analyses for each
metastatic site were performed after defining a region of interest and quantified with the Living
Image software (Caliper LifeSciences). Values were expressed as relative light units (RLU).
After the experimental period, the animals were sacrificed, and tibiae and fibulae were dis-
sected, decalcified and the tissues were processed for paraffin embedding and sectioning
(5.0 μM sections) for histomorphometrical and immunohistochemical analysis.
TRAMPModel
TRAMP mice (C57BL/6-Tg(TRAMP)8247Ng/J), were purchased from The Jackson Labora-
tory [24]. Heterozygous females were maintained on a pure C57BL/6J background by cross-
breeding with non-transgenic C57BL/6 males (Charles River Laboratories, France). Transgenic
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animals were identified by PCR analysis of tail DNA, as described by [27]. The methodology was
based on previous studies using TRAMPmice [28–35]. The XRP44X-treatment protocol was
approved by the IGBMC/ICS Ethics Committee (N° 2011–009, 2012–110). 15-week-old WT and
heterozygous TRAMPmale mice were treated with either XRP44X (1.0 mg/kg) or vehicle
(DMSO, Sigma-Aldrich, D5879) by intraperitoneal injection at the same time of day, 6 days per
week, from 15 to 29 weeks of age, inclusive. The solutions (XRP44X in 30% DMSO in PBS, or
30% DMSO in PBS) were prepared immediately before use and the maximum volume of injec-
tion was 100 μL. The numbers of mice per group were: 14WT vehicle, 12WT XRP44X, 21
TRAMP vehicle and 21 TRAMP XRP44X. General health was monitored at the time of injection.
Animal body weight was recorded twice a week. Injections of XRP44X were stopped 24 hours
before necropsy. At necropsy, the animals were weighed and euthanized by carbon dioxide
asphyxiation. Animals were dissected and examined for gross pathology, abnormal organ size
and presence of metastases. The genitourinary tract, prepared by removing the bladder, seminal
vesicles and prostate en bloc and draining the bladder, was weighed. The prostate gland was sub-
sequently dissected for further analysis. Various organs were harvested, including the pelvic
lymph nodes, liver, lungs, kidneys and spleen. Tissue samples were placed in 10% v/v phosphate-
buffered formalin for 12–24 h, after which the formalin solution was replaced with 70% ethanol
(v/v). For routine histopathological evaluation, the tissues were paraffin embedded, sectioned
(5.0 μm thickness) and stained with H/E. Organ weights were determined using formalin fixa-
tion, ethanol stored organs. Whole blood and serum analyses were performed by the ICS meta-
bolic exploration platform (References: IP00005077, IP0000004829, IP0000004857, IP0000
004895, IP0000004915, IP0000004949, IP0000005011). For blood cell analysis, 4–5 days before
the end of the XRP44X-treatment protocol, whole blood was taken from periorbital sinuses of
animals that had not been treated for 36 hours and was analysed on the same day. For blood bio-
chemical analysis, whole blood was taken by cardiac puncture during necropsy from animals that
had not been for 48 hours. Plasma was prepared and stored at -20°C before use.
Immunohistochemistry
Immunohistochemistry was performed using antibodies against Elk3 (1:1000, peptide affinity
purified PAb-95 [36] and Sigma Prestige1HPA001600) and P-Elk3 (1:2500, peptide affinity
purified MAb-2F3 [8]) and ABC Vectastain kits (Vector laboratories, PK-6101, PK-6102). Tis-
sue slides were heated on a hot plate (5 min 58°C), cleared with Histosol (2 x 3`min), washed
with 100% ethanol (2 x 3 min), 95% ethanol (2 x 3 min), 70% ethanol (2 x 3 min), water (3
min), heated in a pressure cooking in 10mM sodium citrate (5 min 125°C, 20 min cooling in
the cooker), washed with PBS-T (5 min), blocked (goat serum in PBS-T, 1 h), incubated with
primary Ab (1:1000 in blocking serum in PBS-T, 4°C, 14 h), washed with PBS-T (2 x 5 min),
incubated with secondary Ab (in blocking serum in PBS-T, 1 h), washed with PBS-T (2 x 5
min), PBS (2 x 5 min), incubated with ABC reagent in PBS (30 min), washed with PBS (5 min),
incubated with DAB (2–10 min), washed with water (1 min), stained with Harris haematoxylin
(2 sec), washed with water (30 sec), 70% ethanol (1 min), 100% ethanol 2 x 1 min), and incu-
bated with Histosol (2 x 1 min). Staining was quantified by counting the total numbers of
unstained and stained cells in 3–4 representative fields. The numbers counted for the LLC1
xenografts were: control and PAb-95, 158 total, 90 stained; XRP44X and PAb-95, 537 total, 54
stained; control and MAb-2F3, 580 total, 57 stained; XRP44X and MAb-2F3, 540 total and 70
stained. For dorsolateral prostates from mice, the numbers were: wild type PAb-95, 164 total,
47 stained; TRAMP PAb-95, 449 total, 330 stained; TRAMP vehicle MAb-2F3 vs. TRAMP
XRP44X an average of 179 stained cells were counted from the selected dorsolateral prostate
microscopic fields.
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Statistical Analysis
Fisher’s exact test or Student t tests were used for statistical analysis. P 0.05 were considered
to be significant.
Results
XRP44X Inhibits Cell Tumour Formation by Xenografts in Nude Mice
In order to study the effects of XRP44X on tumour growth and metastasis in-vivo, two cell
lines were used, LLC1 (LL/2) Lewis Lung Carcinoma [37] and C6 glioma [38] cells. We previ-
ously reported that XRP44X inhibited FGF-2-induced Elk3 phosphorylation in sevral cell lines
[18]. Similarly, we found that XRP44X clearly inhibited FGF-2-induced Elk3 phosphorylation
in both C6 (S1A Fig) and LL/2 (LLC1) (S1B Fig) (compare FGF-2 induced XRP44X (lanes 4, 5)
and U0126 (lanes 1)] treated with FGF-2 induced XRP44X untreated (lanes 3) and non-
induced non-treated (lanes 2, 6). LL/2 (LLC1) and C6 cells were injected subcutaneously into
nude mice, and after 6 days the mice were injected daily in the peritoneum with 1 mg/kg of
XRP44X or vehicle alone. Tumour volume was estimated by measuring with callipers (Fig 1A)
and by weighing the tumours after the mice were sacrificed (Fig 1B). Metastases were counted
by visual examination of the lungs (Fig 1C). XRP44X inhibited the growth of primary tumours
formed by both cell lines, as well as the final weight of the tumours at sacrifice. XRP44X also
decreased the number of metastases compared to the controls. Similar results were obtained in
three separate experiments, in which 5 mice were used for each condition and cell line (data
not shown). There were no evident signs of toxicity of XRP44X, taking into account the appear-
ance and general behaviour of the mice during the experiment, and the overall morphology of
the major organs after sacrifice (data not shown). These results show that XRP44X decreases
the growth of tumours and the formation of metastases in nude mice.
In order to investigate the mechanisms by which XRP44X inhibits tumour growth, cancer-
related gene expression levels were determined using RNA isolated from XRP44X and mock
treated tumours and ATLASTM Mouse Cancer 1.2 Arrays. Genes that were up or down regu-
lated in XRP44X treated C6 and LL/2 (LLC1) tumours (1.5 or0.67 fold, 203 genes, see S1
Table) were ranked and analysed with the GSEA v2.1.0 Java desktop application (Gene set
enrichment analysis–Broad Institute), with the gene matrixes available from the GSEA website
(c1 to c7, v5.0). Gene sets with FDR<25%, or nominal p values<5% were considered. The
genes were classified into families using the GSEA webtool [39, 40] (S2 Fig). There is a signifi-
cant negative enrichment for genes with promoter regions (-2 kb, +2kb) containing the consen-
sus binding motif for Elk1 (SCGGAAGY), which is also the consensus binding motif for Elk3,
determined by GREAT mSigDB predicted promoter motif analysis of the most significant Elk3
peaks (p<E-15) from ChIP-seq data [7]. There is also negative enrichment for genes up-regu-
lated in MEWO cells (melanoma) after 48h of methionine deprivation, and positive enrich-
ment for genes with promoter regions [-2kb,2kb] around transcription start site containing the
motif GGGTGGRR which matches annotation for PAX4: paired box gene 4 and genes up-reg-
ulated in NHEK cells (normal epidermal keratinocytes) after UVB irradiation. The negative
enrichment for genes containing Elk1/Elk3 binding motifs is expected, since XRP44X was iso-
lated in a screen for inhibition of Elk3 transcription-factor activity [18].
XRP44X Inhibits Tumour Burden in a Prostate Cancer Bone Metastasis
Model
The anti-metastatic properties of XRP44X were further explored with a widely used animal
model of bone metastasis, in which cancer cells expressing luciferase are inoculated into the left
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ventricle of immune-deficient mice and metastatic growth is followed by bioluminescence
imaging (BLI) [41]. Prostate cancer cells expressing luciferase (PC-3M-Pro4/luc+) were inocu-
lated into 4 week old BALB/c nu/nu animals, the mice were treated daily by intra-peritoneal
injections of 1 mg/kg XRP44X or vehicle starting at day 0, (10 per group), and the mice were
weighed. Growth of prostate cancer cells was monitored by BLI. After 24 days, the animals
were sacrificed and rear limb bones were dissected and visualised to evaluate tumour presence
and size. Treatment with XRP44X inhibited metastatic tumour burden, as measured by BLI
(Fig 2A). There was no significant difference in the weight of the animals at the end of the
experiment, and the decrease at early time points was similar to that observed with Combretas-
tatin A4 (S3 Fig), which has properties similar to XRP44X [18]. These results suggest that
Fig 1. XRP44X inhibits tumour growth andmetastasis in nudemice.Cells were injected subcutaneously
into nude mice, and after 6 days the mice were treated daily by intraperitoneal injection of XRP44X (1 mg/kg).
(A) Tumour volume. One representative result is shown, and similar inhibition was observed in four other
mice for each condition and cell line. Comparable results were obtained in three separate experiments. (B)
Tumour weight after sacrifice. The average weight and standard deviation for 5 mice per condition is shown
(p<0.05). (C) Lung metastases. The lungs were excised after sacrifice, photographed and visible metastases
were counted. The averages and standard deviations for 5 lungs per condition are shown.
doi:10.1371/journal.pone.0159531.g001
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XRP44X has limited toxicity, similar to Combretastatin A4 that is used in clinical trials. In
order to follow the tumours at earlier stages, a related cell line was used, PC-3M-Pro4/luc2,
that expresses an enhanced firefly luciferase with superior expression [42]. Metastatic tumour
burden was found to be decreased by XRP44X at earlier time points, and the decrease became
greater at the later time points (Fig 2B), essential confirming and consolidating the results with
the other cell line.
To confirm these observations and study the mechanisms further, tibia and fibula from the
PC-3Mpro4/luc+ experiment were analysed for the number and size of the tumours, by sectioning
and observing every fifth slide after H&E staining. In XRP44X-treated mice, there were fewer sec-
tions with metastases, the metastases were of smaller size and were present in fewer animals (S4
Fig). In the vehicle-treated group, two mice had more than one tumour in the bone. Tumours
were detected in the tibia, but not in the fibula (data not shown). Overall, these morphological
findings confirm the BLI data. In order to detect Elk3, sections were stained with a human Elk3
antibody. There were strong nuclear signals in the metastatic human cells, and not in surrounding
mouse tissues, as expected from the specificity of the antibody for human Elk3. The staining was
similar for both experimental groups (data not shown). These results show that Elk3 is expressed
in the metastases, and, although decreases in Elk3 expression in individual cells of XRP44X treated
animals were not evident, there were fewer cells with Elk3 in the treated animals.
XRP44X Inhibits Tumour Progression in the TRAMP Prostate Cancer
Model
The effect of XRP44X on tumour progression in a spontaneous cancer mouse model was ana-
lysed using transgenic adenocarcinoma of the mouse prostate (TRAMP) mice, one of the most
Fig 2. XRP44X decreases tumour burden in a prostate cancer bonemetastasis model. (A) Analysis of
late stages of metastasis formation. PC-3Mpro4/luc+ cells were inoculated into the left ventricle of the heart of
five-week old BALB/c nu/nu male mice. 10 mice were treated daily with 1 mg/kg of XRP44X, starting at day 0,
and cells were detected by BMI every 3–4 days, starting at day 14. The graph shows metastatic tumour
burden as measured by BLI over the course of the treatment. (B) Analysis of early as well as late stages of
metastasis formation. PC-3Mpro4/luc2* cells were inoculated, and the mice were treated as in (A), except
that 7 mice were used, and BLI measurements were started at day 1. The error bars represent the standard
error of the mean of the BLI signal strength between animals in a group.
doi:10.1371/journal.pone.0159531.g002
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used and characterised models of prostate cancer progression [24]. An intervention type proto-
col was used [28], in which WT and heterozygous TRAMP male mice were treated with either
XRP44X (1.0 mg/kg) or vehicle (DMSO) by intraperitoneal injection at the same time of day, 6
days per week, from 15 to 29 weeks of age (inclusive). The mice were euthanized, organs were
dissected and weighed, and the prostates were fixed, sectioned and H&E stained to determine
pathological grade. The weights of the genitourinary tracts of the XRP44X treated TRAMP
mice were found to be significantly decreased compared to the vehicle treated animals
(p = 0.031, Student’s t-test between the TRAMP groups; Fig 3A). The genitourinary tracts were
in general visibly smaller (see representative photographs, Fig 3B). Pathological grades were
determined according to Greenberg et al. [28]. Prostate lesions in the dorsolateral prostate
lobes were histologically graded as poorly differentiated (PD) adenocarcinoma (sheets of neo-
plastic cells with little or no glandular structures) (example Fig 3C), moderately differentiated
carcinoma (MD, anaplastic sheets of cells that may contain remnants of glandular architec-
ture), well differentiated (WD) carcinoma (increased quantity of small glands) (Fig 3D), PIN
(epithelial stratification and tufting, presence of cribriform structures, elongated nuclei, micro-
papillary projections) (Fig 3E and 3F), and normal (moderate infolding of the mostly columnar
epithelia; no significant abnormalities, NSA). XRP44X significantly decreased the proportion
of tumours with the more advanced poorly differentiated grade in the TRAMP group
(p = 0.008; Fisher’s exact test), and the proportion of TRAMP mice with metastases Fig 3G; S2
Table). There were no significant effects of XPR44X in the wild type mice. These results show
that XRP44X inhibits tumour progression in TRAMP mice.
There were no overt signs of toxicity due to this prolonged treatment with XRP44X. There
were no significant changes in the observable health and behaviour of the animals, body weight
(S5 Fig), and the appearance and weight of the major organs (S6 Fig). Toxicity was further eval-
uated using whole blood and plasma. The whole blood analysis included white and red blood
cells, haemoglobin, haematocrit, mean corpuscular volume and haemoglobin concentration,
neutrophils, lymphocytes, monocytes, eosinophils, large unstained cells, basophils, platelets
and mean platelet volume. There were no significant changes in the majority of these measure-
ments, except for lower amounts of monocytes and basophiles in XRP44X-treated mice (S3
Table; vehicle n = 9, XRP44X n = 10, all wild type). The blood plasma measurements included
of the levels of albumin, total bilirubin, lactate dehydrogenase, aspartate amino transferase, ala-
nine amino transferase and creatinine. There were no significant changes in these parameters
(S4 Table; vehicle n = 12, XRP44X n = 10, all wild type). In summary, amongst these parame-
ters, there were only significant decreases in monocytes (about 25%) and basophils (about
40%).
In order to explore the mechanisms by which XRP44X inhibits tumour progression in
TRAMP mice, immunohistochemical (IHC) staining of dorsolateral prostates and tumours
was performed with anti-Elk3 (PAb-95) and anti-phospho-Elk3 (MAb-2F3) antibodies. The
specificity of the antibodies was authenticated by IHC competition assays with the peptides
used for immunisation (PAb-95 and MAb-2F3) and also using pre-immune serum (for PAb-
95). Nuclear staing was lost in the presence of the peptides, and was not observed compared to
background with the pre-immune serum (S7 Fig). The proportion of cells that stain with the
anti-Elk3 antibody (PAb-95) was found to increase with higher pathological grade (Fig 4A–4C;
A and B show typical examples of PIN and a WD tumour, respectively, and C the quantifica-
tion). XRP44X-treated TRAMP tumours were found to have a lower proportion of stained
cells than the TRAMP vehicle-treated tumours (Fig 4D and 4E; D shows a representative
XRP44X treated WD tumour and E the quantification). Staining with the anti-P-Elk3 antibody
(MAb-2F3) increased in TRAMP tumours compared with wild-type prostates (Fig 4F–4H, 4F
and 4G are representative examples of PIN and PD tumours, respectively, and H the
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Fig 3. Effect of XRP44X treatment on tumorigenesis in the TRAMP prostate cancer mousemodel.Wild
type (WT) and TRAMPmice were treated with XRP44X (1 mg/kg) daily, 6 days per week, from 14 to 29
weeks of age. (A, B) Genitourinary tracts (GUT) were taken as a whole (prostate, seminal vesicles, urinary
bladder). Their weights relative to body weight are shown in (A) (* P = 0.031), and representative
XRP44X Inhibits Tumour Growth and Metastasis in Mice
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quantification). The proportion of nuclei that stained strongly for P-Elk3 decreased in the
XRP44X treated tumours (Fig 4I and 4J; I is a representative example of a XRP44X treated dor-
solateral prostate, and J the quantification). These results indicate that there are changes in
immune-reactivity with antibodies directed against Elk3 and P-Elk3, which is consistent with
decreased expression and phosphorylation of Elk3 due to XRP44X treatment. However, we
cannot exclude, especially in IHC experiments, that other proteins and phosphorylation events
are detected by these antibodies.
Discussion
We report that XRP44X can reduce cancer growth and metastasis in-vivo and has limited tox-
icity. Initial studies on the mechanisms are consistent with XRP44X targeting pathways associ-
ated with Elk3, which is coherent with the screen used to select XRP44X and mechanistic
studies with cell lines [18, 22]. These findings encourage further evaluation and development
of XRP44X for cancer therapy.
photographs are shown in (B). (C-F) The prostates were sectioned, stained with haematoxylin and eosin and
dorso-lateral lobes were graded as described in [28]. Typical sections are shown (see S2 Table for overall
statistics). (G) Proportion of wild type and TRAMPmice with the different prostate pathological grades or
metastases after treatment with vehicle or XRP44X (NSA—no significant anomalies, PIN—prostatic
intraepithelial neoplasia, WD—well differentiated adenocarcinoma, MD—medium differentiated
adenocarcinoma, PD–poorly differentiated adenocarcinoma). Scale bars = 50 μm.
doi:10.1371/journal.pone.0159531.g003
Fig 4. Immunostaining with anti-Elk3 (PAb-95, A-E) and anti-P-Elk3 (MAb-2F3, F-J) of prostates of wild type and TRAMPmice,
with and without XRP4X treatment. (A, B, D, F, G & I) Typical stained sections. Scale bars = 50 μm. (C, E, H & J) Boxplots showing the
proportion of stained cells in sections of dorsolateral prostates from wild type and TRAMP prostates without or with treatment with
XRP44X. Three areas of one slide from each dorsolateral prostate were counted. The numbers of samples were: (C) 12 PIN (prostatic
intraepithelial neoplasia); 32WD (well differentiated tumour); 9 PD (poorly differentiated tumour); (E) 7 WT vehicle (Veh), 6 WT XRP44X,
20 TRAMP vehicle, 21 TRAMP XRP44X; (H) 10WT and 37 TRAMP; (J) 17 vehicle and 20 XRP44X treated TRAMP prostates (** =
P<0.01, *** = P<0.001, Student’s t-test). 29-week-old animals were used.
doi:10.1371/journal.pone.0159531.g004
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We selected for initial in-vivo characterisation of XRP44X three distinct mouse models of
cancer progression and metastasis, subcutaneous xenografts using two highly metastatic cell
lines [C6 and LL/2 (LLC1 cells)], intracardiac injection leading to bone metastasis, and prostate
cancer progression induced by targeted oncogene expression. These models are reasonably
diverse, in terms of: site of tumour growth (subcutaneous, lung, bone and prostate), immuno-
competence of the mouse, tumour cell-type (Lewis Lung Carcinoma, glioma, PC3 prostate can-
cer bone metastasis, and mouse prostate gland) and tumour microenvironment. XRP44X
inhibited tumour growth and decreased metastasis in these systems, suggesting that XRP44X is
generally effective. All mouse preclinical models have their advantages and disadvantages [23,
43, 44]. Generally, ectopic xenografts of tumour cell lines are facile and reproducible, but lack a
native tumour environment and have limited predictive value for most cancers. Some of these
disadvantages are overcome in the metastasis to bone model, in that the bone metastasis-
derived cells migrate to and proliferate in an osseous environment. Transgenic mouse models
such as TRAMP are immunocompetent, generate spontaneous and autochthonous tumours in
an appropriate microenvironment and are more predictive in their therapeutic response, but
are costly and labour intensive. Evaluations of drugs in mice usually follow a progression of
increasing complexity. Potential future directions for the evaluation of XRP44X could include
Patient-Derived Xenografts (PDX) and specific Genetically Engineered Mouse Models
(GEMM). PDX models are becoming increasing available and characterised [45]. They consist
of explanted fragments of tumour tissues in immunosuppressed mice and recapitulate to some
extent the human tumour microenvironment. GEMM express a limited selection of the genetic
changes that drive human malignancies and mimic the genetic background of human tumour
cells [25]. Further evaluation could consider PDX and GEMM driven by mutant Ras, since
XRP44X was developed as an inhibitor of mutant Ras / Erk activated transcription.
The treatment regiment was established in initial trial and error experiments in the subcuta-
neous xenograft models. The choice of conditions was dictated by the solubility of XRP44X in
30% DMSO (final dose 1 mg/kg), the ease of injection (peritoneum) and convenience of the
schedule (daily, same time of day). These conditions were subsequently used for the two other
models. XRP44X inhibited tumour growth when injected at the beginning (preventative proto-
col). This included 6 days after subcutaneous injection to allow tumour take, the day of intra-
cardiac injection and after about 14 weeks in the TRAMP model, following puberty (12 weeks)
and at about the time at which hyperplasia begins to be observed [46]. Later injection of
XRP44X in the xenograft model (after 14 days) also inhibited tumour growth (data not
shown). It remains to be seen if XRP44X is more or less effective when different routes, sched-
ules and doses are used.
XRP44X treatment was associated with limited toxicity. There were no overt effects on gen-
eral health, behaviour, and weights of the body and major organs. There was a transient delay
in weight gain in 5-week old nude mice, which was also observed with Combretastatin A4
(CA4) that was injected at a dose that has a similar efficacy (data not shown). XRP44X was
compared with CA4 since they have similar effects on microtubules and ERK activity [18, 22].
We found that prolonged treatment of wild type mice with XRP44X decreases monocyte and
basophil levels. In contrast, CA4 has been reported to increase granulocytes and decrease neu-
trophils [47]. The effect of XRP44X are relatively specific to certain types of white blood cell, in
contrast to chemotherapeutic agents that usually have more general effects (leukopenia, [48]),
including cholchicine that binds to the same site on tubulin [49]. The current results are prom-
ising and encourage further evaluation of the safety window.
The effects of XRP44X in-vivo are commensurate with previous observations in-vitro [18,
22]. In the subcutaneous xenograft studies, macroarray and GEA analysis showed that
XRP44X down-regulates genes that contain Elk3-like consensus binding motifs in their
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promoter regions (-2 kb, +2kb), as would be expected from down-regulation of the activity of
Elk3 by XRP44X induced inhibition of Ras / Erk phosphorylation. Inhibition of Erk phosphor-
ylation may also inhibit the activity of other Ets factors that bind to similar consensus motifs
[2]. Several other gene sets were also found to be enriched, but their connections with Elk3 are
more tenuous. Methionine depravation affects genes involved in cell cycle control [50], similar
to Elk3 deletion (Gross, 2008 #49}. The positive enrichment for genes with promoters contain-
ing Pax4 motifs could be related to the observations that the paralogue Pax5 interacts with
Elk3 [51], and aberrant Pax5-Elk3 fusion proteins are found in childhood precursor B-cell
acute lymphoblastic leukaemia [52]. The increase in expression of genes that are upregulated
by UVB irradiation [53] could be explained by the fact that Jnk is activated by both UVB [54]
and XRP44X [22]. Furthermore, the Elk3 repressor is regulated by nuclear export in response
to UV [55]. In the intracardiac injection studies, Elk3 was detected in the bone tumours and
after XRP44X treatment the volumes of the tumours decreased. The remaining cells continued
to express Elk3, perhaps because they were not sufficiently exposed to the compound. In the
TRAMP mice, XRP44X decreased the proportion of cells that stained with antibodies raised
against Elk3 and phosphorylated Elk3, as would be generally expected from the activities of
XRP44X. Dephosphorylation of Elk3 could decrease its stability, as suggested by preliminary
observations (unpublished). The effects of XRP44X on gene expression can be expected to be
broader than its effects on Elk3, given that it affects Ras / Erk signalling. Interestingly, other
chemotherapeutic agents have been shown to affect Ets transcription factor activity. For exam-
ple, cytosine arabinoside (ARA-C) was identified as an EWS-Fli1 modulator by comparing the
transcription-signatures of the compound and the fusion protein [56]. Doxorubicin, Trabecta-
dine, Mithramycin and Midostauin also inhibit the EWS-Fli1 transcriptional signature [57,
58]. In addition, pharmacological inhibitors of Poly(ADP-Ribose) Polymerase inhibit
TMPRSS2-ERG activity [59], and Luteolin up-regulates the prostate-derived Ets factor leading
to inhibition of cell proliferation and cell invasion in prostate carcinoma cells [60]. Conversely,
Ets2 in association with mutant p53 can promote resistance to etoposide [61]. XRP44X, like
these other molecules, appear to act at least in part through effects on Ets factor signalling
pathways.
In conclusion, we have found that XRP44X inhibits tumour growth and metastasis in-vivo,
with limited toxicity. This activity could perhaps be mediated in part by its effects on the Ets
transcription factor Elk3. Our study is another example of targeted therapy of a transcription
factor through modulation of regulatory and associated pathways and interacting molecules.
Our current results encourage further evaluation of XRP44X and related molecules for cancer
therapy.
Supporting Information
S1 Fig. XRP44X inhibits FGF-2 induced Elk3 phosphorylation in C6 and LL/2 (LLC1) cells
lines in-vitro. C6 (A) and LL/2 (LLC1) (B) cells were plated in 6 well plates and after 36 hours
(at about 90% confluence) were pre-treated with compounds (0.1 μMXRP44X, 1 μMXRP44X,
10 μMU0126) or vehicle (DMSO) for 4 h, and then induced with FGF-2 (20 ng/ml) for 10
min. Extracts were analysed by Western blotting for phosphoryled-Elk3 (MAb-2F3) and
GAPDH (loading control, MAb374, mouse anti GAPDH IgG1 clone 6C5 Euromedex). Abbre-
viations: Comp = compound; Conc = concentration; 44 = XRP44X; MW =molecular weight;
K = thousand. A similar result was obtained in a biological repeat experiment.
(PDF)
S2 Fig. Gene Set Enrichment Analysis. The ranked list of genes that were up and down regu-
lated in XRP44X treated C6 and LL/2 (LLC1) (203 genes, see S1 Table) was analysed using the
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GSEA v2.1.0 Java desktop application (Gene set enrichment analysis - Broad Institute), with
the available gene matrixes (c1 to c7, v5.0). Gene sets with FDR<25%, or nominal p values
<5% were considered. (A) Gene sets with the highest and lowest enrichments scores (ES) were
selected. SCGGAAGY_V$ELK1_02: Genes with promoter regions [-2kb, 2kb] around tran-
scription start site containing the motif SCGGAAGY which matches annotation for ELK1:
ELK1, member of ETS oncogene family. GGGTGGRR_V$PAX4_03: Genes with promoter
regions [-2kb, 2kb] around transcription start site containing the motif GGGTGGRR which
matches annotation for PAX4: paired box gene 4. KOKKINAKIS_METHIONINE_DEPRIVA-
TION_48HR_UP: Genes up-regulated in MEWO cells (melanoma) after 48h of methionine
deprivation. ENK_UV_RESPONSE_KERATINOCYTE_UP: Genes up-regulated in NHEK
cells (normal epidermal keratinocytes) after UVB irradiation. ES: enrichment score. NES: nor-
malized enrichment score. NOM p-value: nominal p value. FDR: false discovery rate. FWER:
family wise-error rate. (B-E). Enrichment plots.
(PDF)
S3 Fig. Effect of XRP44X treatment on body weight of mice in the bone metastasis model.
The mice in the experiment shown in Fig 2A were weighed during the course of the experi-
ment. A similar number of mice were treated with Combretastatin A4 (1 mg/kg).
(PDF)
S4 Fig. Effect of XRP44X on tumour size (A-D) and Elk3 expression (E, F) analysed by
IHC in the PC-3 pro4/luc+ prostate cancer bone metastasis model. Rear limb bones (tibias
+ fibula) of 7 vehicle and 7 XRP44X treated animals (from the experiment in Fig 2A) were cut
into longitudinal sections (5 μM thickness), and every 5th slide was stained with haematoxylin
and eosin. The sizes of the tumours were estimated by scoring the size on a scale of 1–5 and
summing across the slides with tumour in each animal. There was a statistically significant dif-
ference in the total size between the two groups (P = 0.046, one tailed Student’s test). (D)
Tumours score (as in C) for individual mice. (E, F) Histo- and immuno-staining with PAb
against Elk3 (Sigma Prestige1HPA001600). Adjacent sections were stained with H&E and
anti-Elk3 PAb followed by goat-anti-rabbit, and revealed with DAB peroxidase substrate kit.
The yellow arrowheads point to tumours, the red arrows point in the direction of bone diaphy-
sis and the orange arrows indicate the plane of the bone growth plate. Scale Bars = 100 μM.
(PDF)
S5 Fig. Effect of XRP44X treatment on body weight of TRAMP and wild-type mice.
TRAMP mice were treated for 6 days per week with XRP44X (1 mg/kg) from 15 to 29 weeks of
age. Body weight was recorded twice a week during the course of treatment (WT vehicle
n = 14, WT XRP44X n = 14, TRAMP vehicle n = 16, TRAMP XRP44X n = 20). Body weight
change was converted into percentage for convenience.
(PDF)
S6 Fig. Effect of XRP44X treatment on the weight of organs of wild-type mice.Mice were
treated for 6 days per week with XRP44X (1 mg/kg) from 15 to 29 weeks of age. Organs of ani-
mals in the wild type and TRAMP experimental groups were weighed at the end of the experi-
ment (number of mice (n): wt vehicle n = 14, wt XRP44X n = 12, TRAMP vehicle 21, TRAMP
XRP44X n = 21). A small decrease in the weight (18%) of the spleen of treated wild-type mice
cannot be excluded, given the precision of the technique and the number of animals used.
There was no significant decrease of the weight of spleen in the TRAMP group.
(PDF)
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S7 Fig. Control experiments for antibody specificity using peptide competition (A-C, G-I)
and pre-immune serum (D-F). Adjascent sections (A-C, D-F, G-I) of 30-week old TRAMP
mouse prostates were analysed by IHC with PAb-95 (A-C), pre-immune serum for PAb-95
(D-F) and MAb-2F3 (G-I). (A, G) IHC without added peptide. (B, C, H, I) peptide competi-
tions. The peptides used for immunisation were mixed with the corresponding antibodies at
increasing concentrations (B, H, 1 μg/ml; C, I, 100 μg/ml). Pre-immune serum was used at
three different dilutions (D, 1/1000; E, 1/2500; F, 1/5000). The magnifications are the same for
adjascent sections (A-C, D-F, G-I).
(PDF)
S1 Table. Expression changes of cancer related genes in subcutaneous xenografts. Expres-
sion changes in tumours from LL/2 xenografted animals treated with XRP44X for 18 days and
C6 xenografted animals treated with XRP44X for 26 days compared to corresponding control
tumours, using cancer gene arrays.
(PDF)
S2 Table. Effect of XRP44X treatment on pathology grade in the TRAMP prostate cancer
mouse model. TRAMPmice were treated for 6 days per week with XRP44X (1 mg/kg) from 15
to 29 weeks of age. Prostates were harvested, sectioned and stained with haematoxylin and
eosin. Prostate adenocarcinoma grade was determined as described in Kaplan-Lefko et al. [28]
on one prostate tissue slide per mouse that had a representative amount of dorsolateral pros-
tate. (NSA–no significant anomalies, PIN—prostatic intraepithelial neoplasia, WD–well differ-
entiated adenocarcinoma, MD–medium differentiated adenocarcinoma, PD–poorly
differentiated adenocarcinoma. P = 0.008 between TRAMP groups, Fisher’s exact test).
(PDF)
S3 Table. Effect of XRP44X treatment on whole blood indicators. TRAMPmice were treated
for 6 days per week with XRP44X (1 mg/kg) from 15 to 29 weeks of age. Blood was taken 4–5
days before the end of the treatment from periorbital sinus and analysed on the same day. The
animals were not treated 36 hours before the blood sampling. The table shows averages from
raw values, their standard deviations and Student’s t-test (vehicle n = 9, XRP44X n = 10, all
wild type). Abbreviations: WBC—white blood cells, RBC—red blood cells, HGB—haemoglo-
bin, HCT—haematocrit, MCV—mean corpuscular volume, MCH—mean corpuscular haemo-
globin, MCHC—mean corpuscular haemoglobin concentration, NEUTRO—neutrophils,
LYMPHO—lymphocytes, MONO—monocytes, EOSINO—eosinophils, LUC—large unstained
cells, BASO—basophils, PLT—platelets, MPV—mean platelet volume, st. dev.–standard devia-
tion, T-TEST–Student’s t-test. Whole blood and serum analyses were performed by the ICS
metabolic exploration platform (References: IP00005077, IP0000004829, IP0000004857,
IP0000004895, IP0000004915, IP0000004949, IP0000005011).
(PDF)
S4 Table. Effect of XRP44X treatment on toxicity-related plasma indicators. TRAMP mice
were treated for 6 days per week with XRP44X (1 mg/kg) from 15 to 29 weeks of age. Whole
blood was taken by cardiac puncture to separate plasma, which was stored at -20°C before the
analysis. The animals were not treated 48 hours before the blood sampling. The table shows
averages from raw values, their standard deviations and Student’s t-test (vehicle n = 12,
XRP44X n = 10, all wild type). Abbreviations: T. bilirubin—total bilirubin, LDH—lactate dehy-
drogenase, ASAT—aspartate amino transferase, ALAT—alanine amino transferase, st. dev.–
standard deviation, T-TEST–Student’s t-test.
(PDF)
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